Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Test
1.2.2. End Use
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test
2.2.2. End Use
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Europe PoC TB and Drug-Resistant TB Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High TB Incidence and Drug Resistance Rates
3.2.1.2. Government and Regulatory Support
3.2.1.3. Technological Advancements
3.2.2. Market restraint analysis
3.2.2.1. High Costs of Advanced Diagnostics
3.2.2.2. Regulatory and Compliance Challenges
3.3. Europe PoC TB and Drug-Resistant TB Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Europe PoC TB and Drug-Resistant TB Testing Market: Test Estimates & Trend Analysis
4.1. Europe PoC TB and Drug-Resistant TB Testing Market: Test Dashboard
4.2. Europe PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
4.3. Europe PoC TB and Drug-Resistant TB Testing Market by Test, Revenue
4.4. Molecular Diagnostics
4.4.1. Molecular Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Immunoassays
4.5.1. Immunoassays market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Culture-based Tests
4.6.1. Culture-based Tests market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Serological Tests
4.7.1. Serological Tests market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Europe PoC TB and Drug-Resistant TB Testing Market: End Use Estimates & Trend Analysis
5.1. Europe PoC TB and Drug-Resistant TB Testing Market: End Use Dashboard
5.2. Europe PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
5.3. Europe PoC TB and Drug-Resistant TB Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
5.4. Clinics and Hospitals
5.4.1. Clinics and Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Diagnostic Laboratories
5.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Europe PoC TB and Drug-Resistant TB Testing Market: Regional Estimates & Trend Analysis by Test, and End Use
6.1. Regional Dashboard
6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.3. Europe
6.3.1. UK
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework/ reimbursement structure
6.3.1.3. Competitive scenario
6.3.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.3.2. Germany
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework/ reimbursement structure
6.3.2.3. Competitive scenario
6.3.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.3.3. France
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework/ reimbursement structure
6.3.3.3. Competitive scenario
6.3.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.3.4. Italy
6.3.4.1. Key country dynamics
6.3.4.2. Regulatory framework/ reimbursement structure
6.3.4.3. Competitive scenario
6.3.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.3.5. Spain
6.3.5.1. Key country dynamics
6.3.5.2. Regulatory framework/ reimbursement structure
6.3.5.3. Competitive scenario
6.3.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.3.6. Norway
6.3.6.1. Key country dynamics
6.3.6.2. Regulatory framework/ reimbursement structure
6.3.6.3. Competitive scenario
6.3.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.3.7. Sweden
6.3.7.1. Key country dynamics
6.3.7.2. Regulatory framework/ reimbursement structure
6.3.7.3. Competitive scenario
6.3.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key country dynamics
6.3.8.2. Regulatory framework/ reimbursement structure
6.3.8.3. Competitive scenario
6.3.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.3.9. Russia
6.3.9.1. Key country dynamics
6.3.9.2. Regulatory framework/ reimbursement structure
6.3.9.3. Competitive scenario
6.3.9.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.3.10. Armenia
6.3.10.1. Key country dynamics
6.3.10.2. Regulatory framework/ reimbursement structure
6.3.10.3. Competitive scenario
6.3.10.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.3.11. Azerbaijan
6.3.11.1. Key country dynamics
6.3.11.2. Regulatory framework/ reimbursement structure
6.3.11.3. Competitive scenario
6.3.11.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.3.12. Belarus
6.3.12.1. Key country dynamics
6.3.12.2. Regulatory framework/ reimbursement structure
6.3.12.3. Competitive scenario
6.3.12.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.3.13. Kazakhstan
6.3.13.1. Key country dynamics
6.3.13.2. Regulatory framework/ reimbursement structure
6.3.13.3. Competitive scenario
6.3.13.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.3.14. Rest of Europe
6.3.14.1. Key country dynamics
6.3.14.2. Regulatory framework/ reimbursement structure
6.3.14.3. Competitive scenario
6.3.14.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Vendor Landscape
7.2.1. List of key distributors and channel partners
7.2.2. Key company market share analysis, 2023
7.2.3. Cepheid (Danaher Corporation)
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Molbio Diagnostics
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Abbott Laboratories
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. BD (Becton, Dickinson and Company)
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Roche Diagnostics
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Qiagen
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Lucira Health
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. BioMérieux
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Thermo Fisher Scientific
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Fujifilm (Fujifilm Healthcare)
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. MedMira
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. SD Biosensor
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Trivitron Healthcare
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
List of Tables
Table 1 List Of Abbreviation
Table 2 Europe PoC TB and Drug-Resistant TB Testing Market, By Region, 2018 - 2030 (USD Million)
Table 3 Europe PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 4 Europe PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 5 Germany PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 6 Germany PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 7 UK PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 8 UK PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 9 France PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 10 France PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 11 Italy PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 12 Italy PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 13 Italy PoC TB and Drug-Resistant TB Testing Market, By Sales Channel, 2018 - 2030 (USD Million)
Table 14 Spain PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 15 Spain PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 16 Denmark PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 17 Denmark PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 18 Sweden PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 19 Sweden PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 20 Norway PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 21 Norway PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 22 Russia PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 23 Russia PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 24 Armenia PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 25 Armenia PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 26 Azerbaijan PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 27 Azerbaijan PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 28 Belarus PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 29 Belarus PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 30 Kazakhstan PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 31 Kazakhstan PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
Table 32 Rest of Europe PoC TB and Drug-Resistant TB Testing Market, By Test, 2018 - 2030 (USD Million)
Table 33 Rest of Europe PoC TB and Drug-Resistant TB Testing Market, By End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Europe PoC TB and Drug-Resistant TB Testing Market: Market Outlook
Fig. 14 Europe PoC TB and Drug-Resistant TB Testing Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Europe PoC TB and Drug-Resistant TB Testing Market Driver Impact
Fig. 18 Europe PoC TB and Drug-Resistant TB Testing Market Restraint Impact
Fig. 19 Europe PoC TB and Drug-Resistant TB Testing Market Strategic Initiatives Analysis
Fig. 20 Europe PoC TB and Drug-Resistant TB Testing Market: Test Movement Analysis
Fig. 21 Europe PoC TB and Drug-Resistant TB Testing Market: Test Outlook And Key Takeaways
Fig. 22 Molecular Diagnostics market estimates and forecast, 2018 - 2030
Fig. 23 Immunoassays market estimates and forecast, 2018 - 2030
Fig. 24 Culture-based Tests market estimates and forecast, 2018 - 2030
Fig. 25 Serological Tests market estimates and forecast, 2018 - 2030
Fig. 26 Others market estimates and forecast, 2018 - 2030
Fig. 27 Europe PoC TB and Drug-Resistant TB Testing Market: End Use Movement Analysis
Fig. 28 Europe PoC TB and Drug-Resistant TB Testing Market: End Use Outlook And Key Takeaways
Fig. 29 Clinics and Hospitals market estimates and forecast, 2018 - 2030
Fig. 30 Diagnostic Laboratories market estimates and forecast, 2018 - 2030
Fig. 31 Other market estimates and forecast, 2018 - 2030
Fig. 32 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 UK key country dynamics
Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Germany key country dynamics
Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 France key country dynamics
Fig. 38 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Italy key country dynamics
Fig. 40 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Spain key country dynamics
Fig. 42 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Denmark key country dynamics
Fig. 44 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Sweden key country dynamics
Fig. 46 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Norway key country dynamics
Fig. 48 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Russia key country dynamics
Fig. 50 Russia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Armenia key country dynamics
Fig. 52 Armenia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Azerbaijan key country dynamics
Fig. 54 Azerbaijan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Belarus key country dynamics
Fig. 56 Belarus market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Kazakhstan key country dynamics
Fig. 58 Kazakhstan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Rest of Europe key country dynamics
Fig. 60 Rest of Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Market share of key market players- PoC TB and Drug-Resistant TB Testing market
